It should also be noted that the main goal of this study was to assess the expression and distribution of PACAP/VIP receptors in the NAWM of donors with different clinical subtypes of MS, whereas our immunohistochemical studies in exemplary lesions were solely conducted with the purpose of providing some viable examples of how PACAP/VIP receptor distribution would vary across cell types in and surrounding damaged WM. This evidence concerns the gene ADCYAP1 and myeloid sarcoma.